SCHEMBL2270367

SCHEMBL2270367

Cc1ccc(-c2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 4/20 0.63
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
MAPT P10636 2/20 0.55
PKM P14618 2/20 0.55
GRIK1 P39086 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
SUCNR1 Q9BXA5 1/20 0.54
DHODH Q02127 1/20 0.51
SERPINE1 P05121 2/20 0.51
HDAC2 Q92769 3/20 0.50
HDAC1 Q13547 2/20 0.50
TP53 P04637 1/20 0.50
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
HPGD P15428 2/20 0.49
RAB9A P51151 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ABL1 P00519 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273647 0.88 ACLY (0.60) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2270815 0.88 ACLY (0.67) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2271270 0.86 ACLY (0.64) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2268169 0.85 HDAC1 (0.47) ACLYMEN1KMT2AMAPTTDP1
SCHEMBL2269869 0.85 ACLY (0.67) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2276756 0.85 ACLY (0.56) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2273941 0.84 ACLY (0.59) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2272986 0.84 SERPINE1 (0.60) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2271453 0.84 KMT2A (0.69) ACLYMEN1KMT2AMAPTPKM
SCHEMBL2272049 0.84 ACLY (0.78) ACLYMEN1KMT2AMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885MEN1 3105/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.